FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365512239> ?p ?o ?g. }

• W4365512239 endingPage "CT257" @default.
• W4365512239 startingPage "CT257" @default.
• W4365512239 abstract "Abstract Background: Protein tyrosine phosphatase non-receptor type 2 and type 1 (PTPN2/1) antagonists inhibit PTPN2/1-mediated negative regulation of immune response pathways. They may promote antitumor activity by increasing function of immune cells such as T cells and dendritic cells, inducing cytokine production, increasing antigen presentation, and amplifying interferon gamma-mediated tumor growth arrest. ABBV-CLS-484 and ABBV-CLS-579 are potent, orally bioavailable, first-in-class PTPN2/1 inhibitors that showed promising antitumor activity and were well tolerated in preclinical models. Preclinical data also indicated that PTPN2/1 inhibitors have improved efficacy when combined with PD-1-targeting agents (eg, pembrolizumab) or vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) in multiple tumor models. Here, we describe 2 first-in-human trials of ABBV-CLS-484 or ABBV-CLS-579 as monotherapy and in combination with pembrolizumab or VEGFR TKI in patients with locally advanced/metastatic tumors. Methods: These phase 1, open-label, multicenter, non-randomized trials (ABBV-CLS-484: NCT04777994; ABBV-CLS-579: NCT04417465) comprise dose-escalation (ESC) and dose-expansion (EXP) phases. ESC is guided by a Bayesian optimal interval design based on dose-limiting toxicities. ESC data are used to inform evaluation of EXP cohorts in select tumor types including relapsed/refractory (R/R) head and neck squamous cell carcinoma, R/R non-small cell lung cancer, advanced renal cell carcinoma, and microsatellite instability-high tumors. In both ESC and EXP phases, the study drug (ABBV-CLS-484 or ABBV-CLS-579) is administered orally either alone or in combination with pembrolizumab (200 mg intravenously once every 3 weeks) and is slated to also be administered in combination with a VEGFR TKI. Eligible patients have locally advanced/metastatic tumors for which no effective standard therapy exists (or has failed), and Eastern Cooperative Oncology Group performance status ≤2. Patients (≥18 years) must have received ≥1 prior systemic anticancer therapy for the indication being considered, have relapsed or be refractory to ≥1 prior anti-PD-1/PD-L1 therapy (EXP monotherapy and pembrolizumab combination), or have relapsed after ≤1 (ABBV-CLS-484) or ≥1 (ABBV-CLS-579) prior VEGFR TKI therapy (EXP VEGFR TKI combination). Primary objectives are to assess safety, tolerability, pharmacokinetics, and to determine the recommended expansion dose and/or maximum tolerated dose of ABBV-CLS-484 or ABBV-CLS-579, both as monotherapy and in combination. Evaluation of objective response rate (RECIST v1.1) is a primary objective in EXP phase and a secondary objective in ESC phase. Both studies are active, and as of 30 Nov 2022, 30 (ABBV-CLS-484) and 45 (ABBV-CLS-579) patients had been enrolled in ESC phase. Citation Format: Patricia M. LoRusso, Emiliano Calvo Aller, Noboru Yamamoto, Chia-Chi Lin, Thaddeus Beck, David Sommerhalder, Do-Youn Oh, John D. Powderly, Talia Golan, Linu Sara Abraham, Joel S. Hayflick, Tamar Uziel, Priya Brunsdon, Wijith Munasinghe, Marcia Paddock, Cathleen Brdlik Hartman, Jonathan Powell, Bruno Medeiros, Martha R. Neagu, Benedito A. Carneiro. First-in-human phase 1 studies of PTPN2/1 inhibitors ABBV-CLS-484 and ABBV-CLS-579 in locally advanced or metastatic tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT257." @default.
• W4365512239 created "2023-04-15" @default.
• W4365512239 creator A5000838010 @default.
• W4365512239 creator A5003887338 @default.
• W4365512239 creator A5025042492 @default.
• W4365512239 creator A5027585674 @default.
• W4365512239 creator A5030587345 @default.
• W4365512239 creator A5036709463 @default.
• W4365512239 creator A5037648687 @default.
• W4365512239 creator A5052050860 @default.
• W4365512239 creator A5056227696 @default.
• W4365512239 creator A5059766169 @default.
• W4365512239 creator A5063897579 @default.
• W4365512239 creator A5064953304 @default.
• W4365512239 creator A5068881208 @default.
• W4365512239 creator A5069923958 @default.
• W4365512239 creator A5073467448 @default.
• W4365512239 creator A5078820101 @default.
• W4365512239 creator A5081179675 @default.
• W4365512239 creator A5087671059 @default.
• W4365512239 creator A5089962252 @default.
• W4365512239 creator A5090977453 @default.
• W4365512239 date "2023-04-14" @default.
• W4365512239 modified "2023-09-30" @default.
• W4365512239 title "Abstract CT257: First-in-human phase 1 studies of PTPN2/1 inhibitors ABBV-CLS-484 and ABBV-CLS-579 in locally advanced or metastatic tumors" @default.
• W4365512239 doi "https://doi.org/10.1158/1538-7445.am2023-ct257" @default.
• W4365512239 hasPublicationYear "2023" @default.
• W4365512239 type Work @default.
• W4365512239 citedByCount "0" @default.
• W4365512239 crossrefType "journal-article" @default.
• W4365512239 hasAuthorship W4365512239A5000838010 @default.
• W4365512239 hasAuthorship W4365512239A5003887338 @default.
• W4365512239 hasAuthorship W4365512239A5025042492 @default.
• W4365512239 hasAuthorship W4365512239A5027585674 @default.
• W4365512239 hasAuthorship W4365512239A5030587345 @default.
• W4365512239 hasAuthorship W4365512239A5036709463 @default.
• W4365512239 hasAuthorship W4365512239A5037648687 @default.
• W4365512239 hasAuthorship W4365512239A5052050860 @default.
• W4365512239 hasAuthorship W4365512239A5056227696 @default.
• W4365512239 hasAuthorship W4365512239A5059766169 @default.
• W4365512239 hasAuthorship W4365512239A5063897579 @default.
• W4365512239 hasAuthorship W4365512239A5064953304 @default.
• W4365512239 hasAuthorship W4365512239A5068881208 @default.
• W4365512239 hasAuthorship W4365512239A5069923958 @default.
• W4365512239 hasAuthorship W4365512239A5073467448 @default.
• W4365512239 hasAuthorship W4365512239A5078820101 @default.
• W4365512239 hasAuthorship W4365512239A5081179675 @default.
• W4365512239 hasAuthorship W4365512239A5087671059 @default.
• W4365512239 hasAuthorship W4365512239A5089962252 @default.
• W4365512239 hasAuthorship W4365512239A5090977453 @default.
• W4365512239 hasConcept C121608353 @default.
• W4365512239 hasConcept C126322002 @default.
• W4365512239 hasConcept C143998085 @default.
• W4365512239 hasConcept C2777701055 @default.
• W4365512239 hasConcept C2780057760 @default.
• W4365512239 hasConcept C502942594 @default.
• W4365512239 hasConcept C71924100 @default.
• W4365512239 hasConceptScore W4365512239C121608353 @default.
• W4365512239 hasConceptScore W4365512239C126322002 @default.
• W4365512239 hasConceptScore W4365512239C143998085 @default.
• W4365512239 hasConceptScore W4365512239C2777701055 @default.
• W4365512239 hasConceptScore W4365512239C2780057760 @default.
• W4365512239 hasConceptScore W4365512239C502942594 @default.
• W4365512239 hasConceptScore W4365512239C71924100 @default.
• W4365512239 hasIssue "8_Supplement" @default.
• W4365512239 hasLocation W43655122391 @default.
• W4365512239 hasOpenAccess W4365512239 @default.
• W4365512239 hasPrimaryLocation W43655122391 @default.
• W4365512239 hasRelatedWork W2342781363 @default.
• W4365512239 hasRelatedWork W2610751918 @default.
• W4365512239 hasRelatedWork W2777867648 @default.
• W4365512239 hasRelatedWork W2786497694 @default.
• W4365512239 hasRelatedWork W2904110710 @default.
• W4365512239 hasRelatedWork W2969782175 @default.
• W4365512239 hasRelatedWork W3153432702 @default.
• W4365512239 hasRelatedWork W3161613553 @default.
• W4365512239 hasRelatedWork W3215044659 @default.
• W4365512239 hasRelatedWork W4310753418 @default.
• W4365512239 hasVolume "83" @default.
• W4365512239 isParatext "false" @default.
• W4365512239 isRetracted "false" @default.
• W4365512239 workType "article" @default.